Breast Cancer
The adenoviral type 5 E1A gene sensitizes breast tumors to paclitaxel
Published in Gene Therapy Weekly, November 4th, 2004
"Paclitaxel (Taxol) is a promising frontline chemotherapeutic agent for the treatment of human breast and ovarian cancers. The adenoviral type 5 E1A gene has been tested in multiple clinical trials for its anticancer activity. E1A has also been shown to sensitize paclitaxel-induced killing in E1A-expressing cells," researchers in the United States report.
"Here, we show that E1A can sensitize paclitaxel-induced apoptosis in breast cancer cells in a gene therapy setting by an orthotopic mammary tumor model. We first showed that expression of E1A enhanced in vitro paclitaxel...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-11-04)
More Articles from Gene Therapy Weekly
- Bioreactors
Polycation-mediated precipitation captures plasmid DNA from alkaline lysate - Pancreatic Cancer
Suppressed synthesis of HMGA1 protein treats pancreatic carcinomas in mice - Tumor Suppression
Low-voltage electroporation augments antiangiogenic cancer gene therapy - Vector Development
Herpesvirus-based vector guides fusion protein to cancer cells - Acute Myeloid Leukemia
Loss of clone with FLT3 gene mutation at relapse does not improve AML prognosis - Alzheimer Disease
Biotechcompany scientist presented with award from Alzheimer Association - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
